Is Gilead Sciences, Inc. (NASDAQ:GILD) undervalued? Prominent investors are becoming more confident. The number of bullish hedge fund bets moved up by 10 lately.

Johnson & Johnson (NYSE:JNJ)'s hepatitis C drug, simeprevir, recently received Priority Review status from the FDA. It was a surprising validation for Johnson & Johnson (NYSE:JNJ)'s mid-stage project.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company's Marketing Authorisation Application (MAA) for sofosbuvir, a once-daily oral nucleotide analogue inhibitor for the treatment of chronic hepatitis C virus (HCV) infection, which was ...

Gilead Sciences Inc. (GILD) said the marketing authorization application for its new hepatitis C drug has been validated by the European Medicines Agency and granted accelerated assessment.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from a Phase 2 study (Study 101-08) evaluating idelalisib (formerly GS-1101), an investigational, targeted, oral inhibitor of PI3K delta, in combination with rituximab for older patients with ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that its corporate presentation will be webcast from the 2013 UBS Global Healthcare Conference in New York.

San Diego, CA -- (SBWIRE) -- 05/21/2013 -- An investigation on behalf of investors of Gilead Sciences, Inc. (NASDAQ:GILD) shares over potential securities laws violations by Gilead Sciences and certain of its directors and officers in connection ...

Calls were the options of choice on Gilead Sciences, Inc. (NASDAQ:GILD) yesterday, with roughly 27,000 contracts crossing the tape during the course of the session.

loading. (RTTNews.com) - Gilead Sciences Inc. ( GILD ) will present at the 2013 UBS Global Healthcare Conference in ,New York City .

Gilead Sciences Inc.'s (GILD) first-quarter sales rose a disappointing 8.4% as increased traction for the newer additions to the company's HIV franchise wasn't enough to offset customers stocking up on its antiviral drugs ahead of price increases ...